Achillion Pharmaceuticals, Inc. is a complement focused, patient-driven company. Our mission is to transform the lives of patients and families affected by rare diseases of the complement system. We are committed to delivering on the promise of complement-based therapeutics, including our portfolio of factor D inhibitor compounds, as well as educating and supporting the patient and healthcare communities. Achillion is currently conducting global, Phase 2 clinical trials to investigate oral, factor D inhibitors as a potential treatment strategy for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy. Additional information on the ongoing clinical trials and available resources are provided below. Learn more about Achillion.
For additional information on Achillion’s PNH clinical trials, please visit:
For information on Achillion’s C3G clinical trials, please visit:
WeC3G Patient Support Initiative
C3G Patient and Caregiver Presentation (Nov 2018)
Natural History Study
C3G Patient-Focused Drug Development